BioTuesdays

Category - Markets

Markets

Brookline starts Assertio Holdings at buy; PT $3.50

Brookline Capital Markets launched coverage of Assertio Holdings (NASDAQ:ASRT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 2. Assertio is a pharmaceutical company that recently...

June 3, 2020
Allena Pharmaceuticals Logo
Markets

HCW starts Allena Pharma at buy; PT $10

H.C. Wainwright launched coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $10 price target. The stock closed at $1.68 on May 29. Allena is developing reloxaliase, an orally administered enzyme...

June 1, 2020
Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020
Mersana Therapeutics Logo
Markets

Analysts up Mersana Therapeutics PT to $21

Analysts for SVB Leerink and BTIG raised their price targets for Mersana Therapeutics (NASDAQ:MRSN) to $21 from $12 and $14, respectively, citing positive interim data from the expansion portion of the company’s Phase 1...

May 27, 2020
cohbar-logo
Markets

Brookline starts CohBar at buy; PT $10

Brookline Capital Markets initiated coverage of CohBar (NASDAQ:CWBR) with a “buy” rating and $10 price target. The stock closed at $2.63 on May 26. CohBar is developing CB4211, a novel and optimized analog of MOTS-c, a...

May 27, 2020
CymaBay
Markets

HCW ups CymaBay Therapeutics to buy; PT $9

H.C. Wainwright upgraded CymaBay Therapeutics (NASDAQ:CBAY) to “buy” from “neutral,” with a price target of $9, citing a possible lifting of the clinical hold on seladelpar development in liver disease. The stock closed...

May 26, 2020